EBV-associated cancer and autoimmunity: Searching for therapies

Vaccines

Volumn 3, Issue 1, 2015, Pages 74-89

  Capone, Giovanni ^a   Fasano, Candida ^a   Lucchese, Guglielmo ^b   Calabrò, Michele ^a   Kanduc, Darja ^a  

^a UNIVERSITY OF BARI   (Italy)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Anti EBV vaccine; Autoimmunity; Cancer; EBV EBNA1; Low similarity peptides; Peptide matching; Peptide therapy

Indexed keywords

AUTOANTIBODY; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS VACCINE; PEPTIDE; PROTEOME; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ARTICLE; AUTOIMMUNITY; CROSS REACTION; EPSTEIN BARR VIRUS INFECTION; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; INCIDENCE; NEOPLASM; NONHUMAN; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY; VALIDATION PROCESS;

EID: 85016907570     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines3010074     Document Type: Article

References (100)

1. Saha, A.; Robertson, E.S. Epstein-Barr virus-associated B-cell lymphomas: Pathogenesis and clinical outcomes. Clin. Cancer. Res. 2011, 17, 3056–3063.
2. Mueller, N.E.; Grufferman, S. Hodgkin lymphoma. In Cancer Epidemiology and Prevention, 3rd ed.; Schottenfeld, D., Fraumeni, J.F., Jr., Eds.; Oxford University Press: New York, NY, USA, 2006; pp. 872–897.
3. Adam, P.; Bonzheim, I.; Fend, F.; Quintanilla-Martínez, L. Epstein-Barr virus-positive diffuse large B-cell lymphomas of the elderly. Adv. Anat. Pathol. 2011, 18, 349–355.
4. Piccaluga, P.P.; Gazzola, A.; Agostinelli, C.; Bacci, F.; Sabattini, E.; Pileri, S.A. Pathobiology of Epstein-Barr virus-driven peripheral T-cell lymphomas. Semin. Diagn. Pathol. 2011, 28, 234–244.
5. Huang, W.T.; Lin, C.W. EBV-encoded miR-BART20-5p and miR-BART8 inhibit the IFN-γ-STAT1 pathway associated with disease progression in nasal NK-cell lymphoma. Am. J. Pathol. 2014, 184, 1185–1197.
6. Kanazawa, T.; Hiramatsu, Y.; Iwata, S.; Siddiquey, M.N.; Sato, Y.; Suzuki, M.; Ito, Y.; Goshima, F.; Murata, T.; Kimura, H. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-Cell lymphoproliferative diseases. Clin. Cancer. Res. 2014, doi:10.1158/1078-0432.CCR-14-0580.
7. Yen, C.Y.; Lu, M.C.; Tzeng, C.C.; Huang, J.Y.; Chang, H.W.; Chen, R.S.; Liu, S.Y.; Liu, S.T.; Shieh, B.; Li, C. Detection of EBV infection and gene expression in oral cancer from patients in Taiwan by microarray analysis. J. Biomed. Biotechnol. 2009, doi:10.1155/2009/904589.
8. Alibek, K.; Kakpenova, A.; Baiken, Y. Role of infectious agents in the carcinogenesis of brain and head and neck cancers. Infect. Agent. Cancer 2013, doi:10.1186/1750-9378-8-7.
9. Iizasa, H.; Nanbo, A.; Nishikawa, J.; Jinushi, M.; Yoshiyama, H. Epstein-Barr Virus (EBV)-associated Gastric Carcinoma. Viruses 2012, 4, 3420–3439.
10. Incaprera, M.; Rindi, L.; Bazzichi, A.; Garzelli, C. Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity. Clin. Exp. Rheumatol. 1998, 16, 289–294.
11. Poole, B.D.; Gross, T.; Maier, S.; Harley, J.B.; James, J.A. Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments. J. Autoimmun.2008, 31, 362–371.
12. Youinou, P.; Buisson, M.; Berthelot, J.M.; Jamin, C.; Le Goff, P.; Genoulaz, O.; Lamour, A.; Lydyard, P.M.; Seigneurin, J.M. Anti-Epstein-Barr virus-nuclear antigen-1, -2A and -2B antibodies in rheumatoid arthritis patients and their relatives. Autoimmunity 1992, 13, 225–231.
13. Toussirot, E.; Roudier, J. Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: An update. Joint Bone Spine 2007, 74, 418–426.
14. Csuka, D.; Simon, D.; Hóbor, R.; Uray, K.; Prohászka, Z.; Bánlaki, Z.; Jani, P.K.; Szilágyi, Á.; Hudecz, F.; Rajczy, K.; et al. Serum concentration of immunoglobulin G-type antibodies against the whole Epstein-Barr nuclear antigen 1 and its aa35–58 or aa398–404 fragments in the sera of patients with systemic lupus erythematosus and multiple sclerosis. Clin. Exp. Immunol. 2013, 171, 255–262.
15. Rand, K.H.; Houck, H.; Denslow, N.D.; Heilman, K.M. Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J. Neurol. Sci. 2000, 173, 32–39.
16. Hjalgrim, H.; Friborg, J.; Melbye, M. The epidemiology of EBV and its association with malignant disease. In Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis; Arvin, A., Campadelli-Fiume, G., Mocarski, E., Moore, P.S.; Roizman, B., Whitley, R., Yamanishiet, K., Eds.; Cambridge University Press: Cambridge, UK, 2007; Chapter 53.
17. Capone, G.; Calabrò, M.; Lucchese, G.; Fasano, C.; Girardi, B.; Polimeno, L.; Kanduc, D. Peptide matching between Epstein-Barr virus and human proteins. Pathog. Dis.2013, 69, 205–212.
18. Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 (Internet). Available at: http://globocan.iarc.fr (accessed on 13 December 2013).
19. Browne, P.; Chandraratna, D.; Angood, C.; Tremlett, H.; Baker, C.; Taylor, B.V.; Thompson, A.J. Atlas of multiple sclerosis 2013: A growing global problem with widespread inequity. Neurology 2014, 83, 1022–1024.
20. Uramoto, K.M.; Michet, C.J., Jr.; Thumboo, J.; Sunku, J.; O’Fallon, W.M.; Gabriel, S.E. Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum.1999, 42, 46–50.
21. Gibofsky, A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am. J. Manag. Care 2012, 18, S295–S302.
22. Kanduc, D. Immunogenicity in peptide-immunotherapy: From self/nonself to similar/dissimilar sequences. Adv. Exp. Med. Biol. 2008, 640, 198–207.
23. Kanduc, D. “Self-nonself” peptides in the design of vaccines. Curr. Pharm. Des.2009, 15, 3283–3289.
24. Kanduc, D. Protein information content resides in rare peptide segments. Peptides 2010, 31, 983–988.
25. Kanduc, D. The self/nonself issue: A confrontation between proteomes. SelfNonself 2010, 1, 255–258.
26. Zeng, M.S.; Li, D.J.; Liu, Q.L.; Song, L.B.; Li, M.Z.; Zhang, R.H.; Yu, X.J.; Wang, H.M.; Ernberg I.; Zeng, Y.X. Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient. J. Virol. 2005, 79, 15323–15330.
27. Wu, C.H.; Yeh, L.S.; Huang, H.; Arminski, L.; Castro-Alvear, J.; Chen, Y.; Hu, Z.; Kourtesis, P.; Ledley, R.S.; Suzek, B.E.; et al. The protein information resource. Nucleic Acids Res. 2003, 31, 345–347.
28. Vita, R.; Zarebski, L.; Greenbaum, J.A.; Emami, H.; Hoof, I.; Salimi, N.; Damle, R.; Sette, A.; Peters, B. The immune epitope database 2.0. Nucleic Acids Res. 2010, 38, D854–D862.
29. Thompson, J.D.; Higgins, D.G.; Gibson, T.J. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22, 4673–4680.
30. Benjamin, D.C.; Berzofsky, J.A.; East, I.J.; Gurd, F.R.N.; Hannum, C.; Leach, S.J.; Margoliash, E.; Michael, J.G.; Miller, A.; Prager, E.M.; et al. The antigenic structure of proteins: a reappraisal. Annu. Rev. Immunol. 1984, 2, 67–101.
31. Lerner, R.A. Tapping the immunological repertoire to produce antibodies of predetermined specificity. Nature 1982, doi:10.1038/299592a0.
32. Sutcliffe, J.G.; Shinnick, T.M.; Green, N.; Lerner, R.A. Antibodies that react with predetermined sites on proteins. Science 1983, 219, 660–666.
33. Shinnick, T.M.; Sutcliffe, J.G.; Green, N.; Lerner, R.A. Peptide-elicited protein-reactive antibodies in molecular biology and medicine. J. Invest. Dermatol. 1984, 83, 112S–115S.
34. Niman, H.L.; Houghten, R.A.; Walker, L.E.; Reisfeld, R.A.; Wilson, I.A.; Hogle, J.M.; Lerner, R.A. Generation of protein-reactive antibodies by short peptides is an event of high frequency: Implications for the structural basis of immune recognition. Proc. Natl. Acad. Sci. USA 1983, 80, 4949–4953.
35. Yao, B.; Zhang, L.; Liang, S.; Zhang, C. SVMTriP: A method to predict antigenic epitopes using support vector machine to integrate tri-peptide similarity and propensity. PLOS ONE 2012, 7, e45152.
36. Wang, H.W.; Lin, Y.C.; Pai, T.W.; Chang, H.T. Prediction of B-cell linear epitopes with a combination of support vector machine classification and amino acid propensity identification. J. Biomed. Biotechnol. 2011, doi:10.1155/2011/432830.
37. Singh, H.; Ansari, H.R.; Raghava, G.P.S. Improved method for linear B-cell epitope prediction using antigen’s primary sequence. PLOS ONE 2013, 8, e62216.
38. Hemmer, B.; Kondo, T.; Gran, B.; Pinilla, C.; Cortese, I.; Pascal, J.; Tzou, A.; McFarland, H.F.; Houghten, R.; Martin, R. Minimal peptide length requirements for CD4+ T cell clones-implications for molecular mimicry and T cell survival. Int. Immunol.2000, 12, 375–383.
39. Rothbard, J.B. Peptides and the cellular immune response. Ann. Inst. Pasteur. 1986, 137, 518–526.
40. Rothbard, J.B.; Taylor, W.R. A sequence pattern common to T cell epitopes. EMBO J. 1988, 7, 93–100.
41. Mathews, J.H.; Allan, J.E.; Roehrig, J.T.; Brubaker, J.R.; Uren, M.F.; Hunt, A.R. T-helper cell and associated antibody response to synthetic peptides of the E glycoprotein of Murray Valley encephalitis virus. J. Virol. 1991, 65, 5141–5148.
42. Reddehase, M.J.; Rothbard, J.B.; Koszinowski, U.H. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature 1989, 337, 651–653.
43. Geluk, A.; van Meijgaarden, K.E.; Janson, A.A.; Drijfhout, J.W.; Meloen, R.H.; de Vries, R.R.; Ottenhoff, T.H. Functional analysis of DR17(DR3)-restricted mycobacterial T cell epitopes reveals DR17-binding motif and enables the design of allele-specific competitor peptides. J. Immunol. 1992, 149, 2864–2871.
44. Zeng, W.; Pagnon, J.; Jackson, D.C. The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological function. Mol. Immunol.2007, 44, 3724–3731.
45. Rothbard, J.B.; Pemberton, R.M.; Bodmer, H.C.; Askonas, B.A.; Taylor, W.R. Identification of residues necessary for clonally specific recognition of a cytotoxic T cell determinant. EMBO J. 1989, 8, 2321–2328.
46. Rothbard, J.B.; Gefter, M.L. Interactions between immunogenic peptides and MHC proteins. Annu. Rev. Immunol. 1991, 9, 527–565.
47. Sant’Angelo, D.B.; Robinson, E.; Janeway, C.A., Jr.; Denzin, L.K. Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor. Eur. J. Immunol.2002, 32, 2510–2520.
48. Willers, J.; Capone, G.; Lucchese, A. Peptides: An arrival point in cancer vaccinology. Front. Biosci. 2012, 4, 1381–1392.
49. Kanduc, D. Homology, similarity, and identity in peptide epitope immunodefinition. J. Pept. Sci. 2012, 18, 487–494.
50. Kanduc, D. Pentapeptides as minimal functional units in cell biology and immunology. Curr. Protein Pept. Sci. 2013, 14, 111–120.
51. Rowe, M.; Rowe D.T.; Gregory, C.D.; Young, L.S.; Fartell, P.J.; Rupani, H.; Rickinson, A.B. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt’s lymphoma cells. EMBO J. 1987, 6, 2743–2751.
52. Sivachandran, N.; Dawson, C.W.; Young, L.S.; Liu, F.F.; Middeldorp, J.; Frappier, L. Contributions of the Epstein-Barr virus EBNA1 protein to gastric carcinoma. J. Virol. 2012, 86, 60–68.
53. Tsang, C.W.; Lin, X.; Gudgeon, N.H.; Taylor, G.S.; Jia, H.; Hui, E.P.; Chan, A.T.; Lin, C.K.; Rickinson, A.B. CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes. J. Virol. 2006, 80, 8263–8266.
54. Long, H.M.; Chagoury, O.L.; Leese, A.M.; Ryan, G.B.; James, E.; Morton, L.T.; Abbott, R.J.; Sabbah, S.; Kwok, W.; Rickinson, A.B. MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. J. Exp. Med.2013, 210, 933–949.
55. Long, H.M.; Haigh, T.A.; Gudgeon, N.H.; Leen, A.M.; Tsang, C.W.; Brooks, J.; Landais, E.; Houssaint, E.; Lee, S.P.; Rickinson, A.B.; et al. CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J. Virol. 2005, 79, 4896–4907.
56. Capone, G.; Fasano, C.; Lucchese, G.; Calabrò, M.; Kanduc D. Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, Italy. Unpublished data, 2014.
57. Macalma, T.; Otte, J.; Hensler, M.E.; Bockholt, S.M.; Louis, H.A.; Kalff-Suske, M.; Grzeschik, K.H.; von der Ahe, D.; Beckerle, M.C. Molecular characterization of human zyxin. J. Biol. Chem. 1996, 271, 31470–31478.
58. Sheng, Y.; Hong, J.H.; Doherty, R.; Srikumar, T.; Shloush, J.; Avvakumov, G.V.; Walker, J.R.; Xue, S.; Neculai, D.; Wan, J.W.; et al. A human ubiquitin conjugating enzyme (E2)-HECT E3 ligase structure-function screen. Mol. Cell. Proteomics 2012, 11, 329–341.
59. Schütte, J.; Viallet, J.; Nau, M.; Segal, S.; Fedorko, J.; Minna, J. jun-B inhibits and c-fos stimulates the transforming and trans-activating activities of c-jun. Cell 1989, 59, 987–997.
60. Szremska, A.P.; Kenner, L.; Weisz, E.; Ott, R.G.; Passegué, E.; Artwohl, M.; Freissmuth, M.; Stoxreiter, R.; Theussl, H.C.; Parzer, S.B.; et al. JunB inhibits proliferation and transformation in B-lymphoid cells. Blood 2003, 102, 4159–4165.
61. Davis-Smyth, T.; Duncan, R.C.; Zheng, T.; Michelotti, G.; Levens, D. The far upstream element-binding proteins comprise an ancient family of single-strand DNA-binding transactivators. J. Biol. Chem.1996, 271, 31679–31687.
62. Chari, A.; Golas, M.M.; Klingenhäger, M.; Neuenkirchen, N.; Sander, B.; Englbrecht, C.; Sickmann, A.; Stark, H.; Fischer, U. An assembly chaperone collaborates with the SMNcomplex to generate spliceosomal SnRNPs. Cell 2008, 135, 497–509.
63. Rivkin, E.; Vella, M.J.; Lahita, R.G. A heterogeneous immune response to an SmD-like epitope by SLE patients. J. Autoimmun.1994, 7, 119–132.
64. Levitskaya, J.; Sharipo, A.; Leonchiks, A.; Ciechanover, A.; Masucci, M.G. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA 1997, 94, 12616–12621.
65. Levitskaya, J.; Coram, M.; Levitsky, V.; Imreh, S.; Steigerwald-Mullen, P.M.; Klein, G.; Kurilla, M.G.; Masucci, M.G. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995, 375, 685–688.
66. Cheng, H.M.; Foong, Y.T.; Sam, C.K.; Prasad, U.; Dillner, J. Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors. J. Clin. Microbiol. 1991, 29, 2180–2186.
67. Leen, A.; Meij, P.; Redchenko, I.; Middeldorp, J.; Bloemena, E.; Rickinson, A.; Blake, N. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4+ T-helper 1 responses. J. Virol. 2001, 75, 8649–8659.
68. Taylor, G.S.; Haigh, T.A.; Gudgeon, N.H.; Phelps, R.J.; Lee, S.P.; Steven, N.M.; Rickinson, A.B. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: Potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J. Virol. 2004, 78, 768–778.
69. Woodberry, T.; Suscovich, T.J.; Henry, L.M.; Davis, J.K.; Frahm, N.; Walker, B.D.; Scadden, D.T.; Wang, F.; Brander, C. Differential targeting and shifts in the immunodominance of Epstein-Barr virus—Specific CD8 and CD4 T cell responses during acute and persistent infection. J. Infect. Dis.2005, 192, 1513–1524.
70. Krüger, S.; Schroers, R.; Rooney, C.M.; Gahn, B.; Chen, S.Y. Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J. Immunother.2003, 26, 212–221.
71. Petersen, J.; Rhodes, G.; Patrick, K.; Roudier, J.; Vaughan, J.H. Human T cell responses to the Epstein-Barr nuclear antigen-1 (EBNA-1) as evaluated by synthetic peptides. Cell Immunol.1989, 123, 325–333.
72. Petersen, J.; Rhodes, G.; Roudier, J.; Vaughan, J.H. Altered immune response to glycine-rich sequences of Epstein-Barr nuclear antigen-1 in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum.1990, 33, 993–1000.
73. Taylor, G.S.; Long, H.M.; Haigh, T.A.; Larsen, M.; Brooks, J.; Rickinson, A.B. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J. Immunol. 2006, 177, 3746–3756.
74. Depil, S.; Moralès, O.; Castelli, F.A.; Delhem, N.; François, V.; Georges, B.; Dufossé, F.; Morschhauser, F.; Hammer, J.; Maillère, B.; et al. Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies. J. Immunother.2007, 30, 215–226.
75. Moralès, O.; Depil, S.; Mrizak, D.; Martin, N.; Ndour, P.A.; Dufosse, F.; Miroux, C.; Coll, J.; de Launoit, Y.; Auriault, C.; et al. EBV Latency II-derived peptides induce a specific CD4+ cytotoxic T-cell activity and not a CD4+ regulatory T-cell response. J. Immunother. 2012, 35, 254–266.
76. Voo, K.S.; Peng, G.; Guo, Z.; Fu, T.; Li, Y.; Frappier, L.; Wang, R.F. Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res. 2005, 65, 1577–1586.
77. Smith, C.; Cooper, L.; Burgess, M.; Rist, M.; Webb, N.; Lambley, E.; Tellam, J.; Marlton, P.; Seymour, J.F.; Gandhi, M.; et al. Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. J. Immunol. 2006, 177, 4897–4906.
78. Demachi-Okamura, A.; Ito, Y.; Akatsuka, Y.; Tsujimura, K.; Morishima, Y.; Takahashi, T.; Kuzushima, K. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells. Cancer Sci. 2008, 99, 1633–1642.
79. Sundström, P.; Nyström, M.; Ruuth, K.; Lundgren, E. Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis. J. Neuroimmunol. 2009, 215, 102–107.
80. Gurer, C.; Strowig, T.; Brilot, F.; Pack, M.; Trumpfheller, C.; Arrey, F.; Park, C.G.; Steinman, R.M.; Münz, C. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 2008, 112, 1231–1239.
81. Rooney, C.M.; Smith, C.A.; Ng, C.Y.; Loftin, S.; Li, C.; Krance, R.A.; Brenner, M.K.; Heslop, H.E. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995, 345, 9–13.
82. Gu, S.Y.; Huang, T.M.; Ruan, L.; Miao, Y.H.; Lu, H.; Chu, C.M.; Motz, M.; Wolf, H. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev. Biol. Stand. 1995, 84, 171–177.
83. Moutschen, M.; Léonard, P.; Sokal, E.M.; Smets, F.; Haumont, M.; Mazzu, P.; Bollen, A.; Denamur, F.; Peeters, P.; Dubin, G.; et al. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 2007, 25, 4697–4705.
84. Sokal, E.M.; Hoppenbrouwers, K.; Vandermeulen, C.; Moutschen, M.; Léonard, P.; Moreels, A.; Haumont, M.; Bollen, A.; Smets, F.; Denis, M. Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 2007, 196, 1749–1753.
85. Cui, X.; Cao, Z.; Sen, G.; Chattopadhyay, G.; Fuller, D.H.; Fuller, J.T.; Snapper, D.M.; Snow, A.L.; Mond, J.J.; Snapper, C.M. A novel tetrameric gp350 1–470 as a potential Epstein-Barr virus vaccine. Vaccine 2013, 31, 3039–3045.
86. Ruiss, R.; Jochum, S.; Wanner, G.; Reisbach, G.; Hammerschmidt, W.; Zeidler, R. A virus-like particle-based Epstein-Barr virus vaccine. J. Virol. 2011, 85, 13105–13113.
87. Antsiferova, O.; Müller, A.; Rämer, P.C.; Chijioke, O.; Chatterjee, B.; Raykova, A.; Planas, R.; Sospedra, M.; Shumilov, A.; Tsai, M.H.; et al. Adoptive transfer of EBV specific CD8+ T sell clones can transiently control EBV infection in humanized mice. PLOS Pathog. 2014, 10, e1004333.
88. Lutzky, V.P.; Crooks, P.; Morrison, L.; Stevens, N.; Davis, J.E.; Corban, M.; Hall, D.; Panizza, B.; Coman, W.B.; Coman, S.; et al. Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma. Clin. Vaccine Immunol. 2014, 21, 256–259.
89. Ghosh, S.K.; Perrine, S.P.; Faller, D.V. Advances in virus-directed therapeutics against Epstein-Barr Virus-associated malignancies. Adv. Virol. 2012, doi:10.1155/2012/509296.
90. Lünemann, J.D.; Tintoré, M.; Messmer, B.; Strowig, T.; Rovira, A.; Perkal, H.; Caballero, E.; Münz, C.; Montalban, X.; Comabella, M. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann. Neurol. 2010, 67, 159–169.
91. Angelini, D.F.; Serafini, B.; Piras, E.; Severa, M.; Coccia, E.M.; Rosicarelli, B.; Ruggieri, S.; Gasperini, C.; Buttari, F.; Centonze, D.; et al. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLOS Pathog.2013, 9, e1003220.
92. Kannangai, R.; Sachithanandham, J.; Kandathil, A.J.; Ebenezer, D.L.; Danda, D.; Vasuki, Z.; Thomas, N.; Vasan, S.K.; Sridharan, G. Immune responses to Epstein-Barr virus in individuals with systemic and organ specific autoimmune disorders. Indian. J. Med. Microbiol. 2010, 28, 120–123.
93. Mahler, M.; Fritzler, M.J.; Blüthner, M. Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. Arthritis Res. Ther. 2005, 7, R19–R29.
94. Karin, N.; Binah, O.; Grabie, N.; Mitchell, D.J.; Felzen, B.; Solomon, M.D.; Conlon, P.; Gaur, A.; Ling, N.; Steinman, L. Short peptide-based tolerogens without self-antigenic or pathogenic activity reverse autoimmune disease. J. Immunol. 1998, 160, 5188–5194.
95. Tselios, T.; Daliani, I.; Probert, L.; Deraos, S.; Matsoukas, E.; Roy, S.; Pires, J.; Moore, G.; Matsoukas, J. Treatment of experimental allergic encephalomyelitis (EAE) induced by guinea pig myelin basic protein epitope 72–85 with a human MBP(87–99) analogue and effects of cyclic peptides. Bioorg. Med. Chem. 2000, 8, 1903–1909.
96. Lucchese, A.; Mittelman, A.; Lin, M.S.; Kanduc, D.; Sinha, A.A. Epitope definition by proteomic similarity analysis: Identification of the linear determinant of the anti-Dsg3 MAb 5H10. J. Transl Med.2004, doi:10.1186/1479-5876-2-43.
97. Lucchese, A.; Mittelman, A.; Tessitore, L.; Serpico, R.; Sinha A.A.; Kanduc D. Proteomic definition of a desmoglein linear determinant common to Pemphigus vulgaris and Pemphigus foliaceous. J. Transl. Med. 2006, doi:10.1186/1479-5876-4-37.
98. Salato, V.K.; Hacker-Foegen, M.K.; Lazarova, Z.; Fairley, J.A.; Lin, M.S. Role of intramolecular epitope spreading in pemphigus vulgaris. Clin Immunol. 2005, 116, 54–64.
99. Angelini, G.; Bonamonte, D.; Lin, M.S., Lucchese, A.; Mittelman, A.; Serpico, R.; Simone, S.; Sinha, A.A.; Kanduc, D. Characterization of polyclonal antibodies raised against a linear peptide determinant of desmoglein-3. J. Exp. Ther. Oncol. 2005, 5, 1–7.
100. Angelini, G.; Bonamonte, D.; Lucchese, A.; Favia, G.; Serpico, R.; Mittelman, A.; Simone, S.; Sinha, A.A.; Kanduc D. Preliminary data on Pemphigus vulgaris treatment by a proteomics-defined peptide: A case report. J. Transl. Med. 2006, doi:10.1186/1479-5876-4-43.